1. Effects of Low-Dose Amitriptyline on Epigastric Pain Syndrome in Functional Dyspepsia Patients
- Author
-
Jian Xu, Wen-cong Zhou, Shu-Man Jiang, Yao Liu, Jing Liu, and Lin Jia
- Subjects
Adult ,Male ,medicine.medical_specialty ,Physiology ,Amitriptyline ,Epigastric pain ,Pittsburgh Sleep Quality Index ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Hamd ,Humans ,Medicine ,Prospective Studies ,Dyspepsia ,Pantoprazole ,Dose-Response Relationship, Drug ,business.industry ,Therapeutic effect ,Gastroenterology ,Analgesics, Non-Narcotic ,Middle Aged ,Abdominal Pain ,Treatment Outcome ,Before Bedtime ,030220 oncology & carcinogenesis ,Anxiety ,Female ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,medicine.drug - Abstract
To observe the therapeutic effect of low-dose amitriptyline (AMT) on epigastric pain syndrome (EPS) in patients with functional dyspepsia. Sixty patients with EPS were randomly divided into the following two groups for a four-week clinical trial: routine treatment with pantoprazole (RT group) and the AMT group. The RT group was treated with 40 mg of pantoprazole once daily. The AMT group received 25 mg of AMT once daily before bedtime. The Nepean Dyspepsia Index (NDI) checklist, Hamilton Rating Scale of Anxiety/Depression (HAMA/HAMD), and Pittsburgh Sleep Quality Index (PSQI) were employed to evaluate dyspepsia symptoms, psychological distress, and sleep, respectively. All items were similar between the two groups before treatment (0 week). After 4 weeks of treatment, the NDI–symptom checklist score as well as the severity and bothersomeness of EPS in the AMT group was significantly decreased compared with those in the RT group (p
- Published
- 2020